title: AMP-activated protein kinase pathway and bone metabolism.
abstract: There is increasing evidence that osteoporosis, similarly to obesity and diabetes, could be another disorder of energy metabolism. AMP-activated protein kinase (AMPK) has emerged over the last decade as a key sensing mechanism in the regulation of cellular energy homeostasis and is an essential mediator of the central and peripheral effects of many hormones on the metabolism of appetite, fat and glucose. Novel work demonstrates that the AMPK signaling pathway also plays a role in bone physiology. Activation of AMPK promotes bone formation in vitro and the deletion of α or β subunit of AMPK decreases bone mass in mice. Furthermore, AMPK activity in bone cells is regulated by the same hormones that regulate food intake and energy expenditure through AMPK activation in the brain and peripheral tissues. AMPK is also activated by antidiabetic drugs such as metformin and thiazolidinediones (TZDs), which also impact on skeletal metabolism. Interestingly, TZDs have detrimental skeletal side effects, causing bone loss and increasing the risk of fractures, although the role of AMPK mediation is still unclear. These data are presented in this review that also discusses the potential roles of AMPK in bone as well as the possibility for AMPK to be a future therapeutic target for intervention in osteoporosis.
authors: Royal Veterinary College, Royal College Street, London NW1 0TU, UK.
authors: J
authors: J
authors: Jeyabalan
authors: M
authors: M
authors: Shah
authors: B
authors: B
authors: Viollet
authors: C
authors: C
authors: Chenu
mesh_terms: D055372:AMP-Activated Protein Kinases / Q000235:genetics / Q000502:physiology*; D017667:Adipocytes; D000818:Animals; D001842:Bone and Bones / Q000378:metabolism* / Q000502:physiology; D004734:Energy Metabolism; D004789:Enzyme Activation / Q000187:drug effects; D017353:Gene Deletion; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects; D051379:Mice; D010012:Osteogenesis / Q000502:physiology; D010024:Osteoporosis / Q000209:etiology / Q000628:therapy
chemical_list: D007004:Hypoglycemic Agents; D055372:AMP-Activated Protein Kinases